For many, the phrase “women’s health” becomes synonymous with contraception.
However, for those in business development, procurement, or portfolio management, “women’s health” encompasses a far broader scope.
The scope includes maternal health to prevent postpartum haemorrhage, as well as conditions including anaemia, osteoporosis, cancer, and other gynaecological conditions.
There are different product needs across these conditions and at varying levels.
Rapidly increasing demand for women’s health conditions is occurring in the same regions where emerging healthcare systems are developing.
These regions provide the best opportunities for business growth.
Supplying women’s health products presents challenges, including unstable cold chains and variations in tenders and regulations.
This article provides an analysis of the primary markets for women’s health APIs and women’s health formulations, and the barriers to supply.
Understanding these barriers allows companies to strategically align their business for greater opportunity in women’s health products.
The Demand Is Real and Structural, Not Cyclical
The Women’s health market is defined and segmented differently by various sources.
According to IMARC, Fortune Business Insights, and Grand View Research, the global women’s health market will reach between $44.1 billion[1] and $56.85 billion[2] by 2025.

The market at a glance
Estimates show the market will grow between 5.1%[3] and 6.31%[4] each year.
Precedence Research expects hormonal therapies will be the largest drug class in the women’s health market, and The Business Research Company expects the market in Asia will grow the fastest.
What is actually driving it

The causes are more demographic than trend-related:
Two considerations are made for portfolio planning.
First, the demand base encompasses reproductive, maternal, and post-menopausal populations; thus, it is not limited to a single trend in the demand for a specific product.
Second, product demand varies by geography, reflecting differences in the speed of reimbursement by insurance and the timing of procurement by the public sector.
Women’s Health Is Far Larger Than Family Planning
Contraceptives comprise 28.17%[7] (as of 2021) market,, which means approximately 70% of the market consists of other women’s health products.
Women’s health encompasses several therapeutic areas.

Developing products for just one of these areas is less competitive than developing a product for a variety of areas.
Of the several areas, some require more advanced pharmaceutical APIs and, if developed, would earn a high profit margin.
Some pillars are high-volume and price-sensitive; others, such as hormonal oncology and hormone therapy, reward technical capability and documentation.
A portfolio that encompasses several therapeutic areas is preferred.
| Pillar | Representative molecules | Demand driver |
| Reproductive health and contraception | Levonorgestrel; oral and injectable contraceptive APIs | Unmet need; family-planning programmes |
| Maternal health | Oxytocin, misoprostol, carbetocin, tranexamic acid, iron–folic acid | Postpartum haemorrhage; anaemia in pregnancy |
| Menopause and HRT | Estradiol, conjugated estrogens, progesterones | Ageing populations |
| Bone health | Alendronate, risedronate, zoledronic acid, raloxifene | Post-menopausal osteoporosis |
| Hormonal oncology | Tamoxifen, letrozole, anastrozole | Breast cancer incidence; oncology access |
| Gynaecological conditions | PCOS, endometriosis, fibroid therapies | Rising diagnosis rates |
| Female-specific infections | Antifungals; agents for bacterial vaginosis, UTIs | High prevalence |
| Anaemia and micronutrients | Iron salts, folic acid, ferric carboxymaltose | High anaemia prevalence |
Why the Need Goes Unmet and What That Costs
Mothers still die of preventable haemorrhage

PPH is the largest contributor to the global maternal health crisis.
It is estimated that 14 million women experience PPH annually, and over 70,000 women die from it.[8]
It is a particular crisis for women in low- and lower-middle-income countries.
PPH accounts for approximately 99%[9] of postpartum haemorrhage (PPH) -related maternal mortalities in the low- and middle- income countries (LMICs).
The World Health Organization (WHO) recommends the use of uterotonics, mainly oxytocin and misoprostol, for prevention and treatment of PPH.
Carbetocin is heat stable and may prove to be useful in contexts where the cold chain is not functional.
According to a study published in PMC, heat stable carbetocin maintained peptide purity for a period of three years at 30°C and 75% relative humidity.
Contraceptive need outpaces supply
Contraception. In 2017, Guttmacher reported that approximately 214 million women[10] in developing countries did not have access to modern contraceptives.
In the process, they put themselves at risk of unplanned pregnancy. The report serves as a historical benchmark, as figures always vary.
Female cancers are rising where care is scarcest
High-income nations tend to have higher rates of female cancer incidence, while lower-income nations have higher female cancer mortality rates.

Approximately 70% of female[11] cancer deaths occur in low-income nations.
In high-HDI (high Human Development Index) nations, about 1 in 71 women die from breast cancer, while 1 in 27 women in low-HDI nations die from breast cancer.
About 94% of cervical cancer[12] deaths occur in low- and middle-income countries.
The targets in the WHO’s 90-70-90 initiative aim to achieve the elimination of cervical cancer.
The primary barrier to eliminating these female cancers is the availability of essential health interventions.
Often, the interventions required to close these gaps have already been developed.
Mapping the Opportunity: Where Demand Concentrates
Route to market varies by segment. Some demand relies on donor funding and tenders.
Some are public. The rest is commercial.
| Segment | Demand signal | Dominant channel(s) |
| Contraceptives | Recurring; largest single application | Donor (UNFPA) + public + growing private |
| Maternal commodities | High, life-saving | Public procurement + donor programmes |
| Hormonal oncology | Rising with incidence and access | Public + private hospitals |
| Bone health and HRT | Rising with ageing | Increasingly commercial/retail |
| Gynaecological conditions | Rising with diagnosis | Commercial/retail |
| Anaemia and micronutrients | Broad, high-volume | Public + OTC + programmes |
There is a certain standard of quality required of donors.
A 2006 USAID-sponsored report noted UNFPA as a major buyer of hormonal contraceptives and noted Indian manufacturers as strong performers in international tenders, in part, due to strict quality standards.
The authors noted the importance of having a strong quality system for donor funds, but noted that for commercial funds, having a strong distribution system is more important.
The Same Category, Very Different Markets
The Guttmacher Institute finds that when looking at contraceptive needs across the emerging markets, unmet need for modern contraception is the highest in Sub-Saharan Africa (21%), with the highest absolute number (approximately 70 million women) in Southern Asia.
| Region | Where demand concentrates | Market character |
| Sub-Saharan Africa | Maternal health, contraception, cervical cancer, anaemia | Largely donor-funded and public; tender-driven |
| South Asia | High-volume maternal health, anaemia, contraception; rising oncology and HRT | Large public programmes plus growing private |
| Southeast Asia | Contraception, HRT, oncology, gynaecological conditions | Mixed public/private; rising middle class |
| Latin America | Ageing-driven: HRT, osteoporosis, breast and cervical cancer | More commercial; stronger private and insurance markets |
| MENA | Growing across segments | Mostly commercial; regulatory and cultural specificity |
Reasons for the lack of reproductive product access in some regions are regulatory and cultural, not values-related.
India’s Supply Position in Women’s Health
India provides approximately 20% of the world’s generic medicines and has the second-highest number of US FDA-approved facilities, next to the US.
India’s pharmaceutical manufacturing supplies the women’s health supply chain with hormonal contraceptives.

Contraceptives are manufactured for institutional tenders such as the ones issued by the US Agency for International Development (USAID).
Manufacturers in India are moving up the value chain. Currently, India has less than 8% of the global market share for APIs, and as a result, most local manufacturers produce high-potency APIs.
Many pharmaceutical companies have begun constructing High Potency API Suites to manufacture compounds that have occupational exposure limits of less than 1 μg/m³.[13]
India is able to produce a broader range of pharmaceuticals.
Customers will need to determine the containment, quality, and regulatory standards of the local pharmaceutical manufacturers to assess if they are able to supply the desired pharmaceuticals.
The Supply Reality: Why This Category Is Harder to Serve
Being a generalist with an interest in women’s health is risky.
There are four key realities that determine who can serve this area well, and they tend to favour the more technical of us.
| Reality | What it means | Buyer implication |
| Hormonal API containment | Potent, low-dose molecules need production facilities separate from other pharmaceutical products and controlled environments | Verify dedicated hormonal APIs capacity, not shared lines |
| Cold chain and stability | Oxytocin loses potency without refrigeration; heat-stable carbetocin stays stable up to 30°C for at least three years | Confirm stability data for the destination climate |
| Quality and tender barriers | Donor and public tenders expect WHO-GMP, prequalification-grade quality and full stability documentation | Prioritise WHO-PQ/SRA-grade suppliers; model total cost |
| Demand heterogeneity | Channel, funding and culture differ by region | Match product and channel to the market |
FP Analytics found that when foreign aid is cut, funding for reproductive health and rights is drastically reduced.
Because of this, there is financial instability for donor-funded programs, and markets that have shifted programs to national budgets are likely more stable.
What a Capable Women’s Health Supply Partner Looks Like
Buyers need to measure API manufacturers and pharmaceutical manufacturers against the above criteria and determine whether they have verifiable GMPs, the necessary capability to produce the given molecule (and containment, if required), quality and stability, regulatory readiness and prequalification, adequate portfolio, and the ability to produce for donor, public and commercial clients.
According to its public documents, Actiza manufactures more than 25 dosage forms under WHO-GMP.
Actiza produces APIs and pharmaceutical, intermediates, and it has over 550 ready-to-use dossiers.
Suppliers that respond to specific molecule requests generally answer in more detail and are better to work with.
FAQ
Q1. What counts as a women’s health API?
Any active pharmaceutical ingredient (API) associated with conditions that are predominantly male- or female-related, for example, various types of hormones, uterotonics, misoprostol, bone resorptive agents, hormonal oncological agents, iron and folic acid.
Q2. Why is demand for women’s health products rising in emerging markets?
Improvements in diagnosis and treatment, and an increase in public awareness and policy, have led to a sustained and increasing demand in this area.
Q3. Which women’s health segment is the largest?
According to Grand View Research, contraceptives accounted for $19.33 billion or 28.17% of the market in 2021. Additionally, according to Precedence Research, hormonal drugs accounted for the largest market share in 2020.
Q4. Why are hormonal APIs harder to manufacture?
Hormonal APIs are difficult to produce because of their high potency and low dosage forms. Cross-contamination should be avoided, as exposure limits for some hormonal drugs are as low as 1 μg/m³.
Q5. Are women’s health markets in developing countries donor-funded or commercial?
A combination of both. Contraceptives and maternal health products are donor- and government-funded, while hormonal products and gynaecological products are more commercial.
Conclusion
The demand for women’s health medicines in the emerging markets is one of the most stable and consistently strong market opportunities in the pharmaceutical industry.
The global market scope for these medicines is wider and the volume larger than for medicines to prevent and treat family planning.
Women’s health medicines span products for fertility control, contraception, pregnancy, childbirth and post-childbirth health, including breast cancer and menopause.
Sustainable access to these women’s health medicines requires pharmaceutical companies to have the hormonal formulation capability and stability of medicines during transport and storage in developing countries with a varying climate.
If you are creating a women’s health medicines portfolio or wish to evaluate a specific women’s health medicine, contact Actiza.
- https://www.imarcgroup.com/womens-health-market
- https://www.fortunebusinessinsights.com/industry-reports/women-s-health-market-101847
- https://www.grandviewresearch.com/industry-analysis/womens-health-market
- https://www.fortunebusinessinsights.com/industry-reports/women-s-health-market-101847
- https://www.guttmacher.org/fact-sheet/adding-it-up-contraception-mnh-2017
- https://fpanalytics.foreignpolicy.com/2025/08/28/innovation-investment-womens-health/
- https://www.grandviewresearch.com/industry-analysis/womens-health-market
- https://pmc.ncbi.nlm.nih.gov/articles/PMC12145113/
- https://www.who.int/news/item/20-12-2018-who-updates-guidance-to-help-healthcare-workers-prevent-postpartum-haemorrhage
- https://www.guttmacher.org/fact-sheet/adding-it-up-contraception-mnh-2017
- https://www.uicc.org/news-and-updates/news/globocan-2022-latest-global-cancer-data-shows-rising-incidence-and-stark
- https://www.who.int/initiatives/cervical-cancer-elimination-initiative
- https://www.drugpatentwatch.com/blog/indias-growing-importance-in-generic-drug-api-manufacturing/
